Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value? [0.03%]
早期癌症试验中连续剂量水平的药物组合协同作用建模：有什么附加价值？
Mourad Tighiouart,José L Jiménez,Marcio A Diniz et al.
Mourad Tighiouart et al.
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value in including an interaction term to model ...